Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1978 Jan;62(1):7-17.
doi: 10.1111/j.1476-5381.1978.tb07000.x.

Guanethidine-induced vasodilatation in the rabbit, mediated by endogenous histamine

Guanethidine-induced vasodilatation in the rabbit, mediated by endogenous histamine

J A Angus et al. Br J Pharmacol. 1978 Jan.

Abstract

1 The effects of guanethidine (0.5-4 mg/kg i.v.) on arterial pressure, hindlimb blood flow and hindlimb vascular resistance (HVR) were studied in unanesthetized rabbits subjected to "total" autonomic block. 2 Evidence that this response was mediated by histamine release was that (a) 3H-labelled histamine levels in the hindlimb venous blood rose substantially after guanethidine; (b) infusion of exogenous histamine caused an inhibition of the guanethidine-induced vasodilatation; and (c) competitive antagonism of the response was obtained with the H2-antagonist burimamide. 3 There was good correlation between the [3H]-histamine ;elease and the time course of the vasodilator response. Glyceryl trinitrate infusions that lowered HVR substantially, did not cause release of histamine. 4 Reserpine, desipramine and indomethacin pretreatment did not alter the vasodilator response to guanethidine. 5 The guanethidine vasodilator response was not influenced by the H1-antagonist mepyramine or by the other H2-antagonists, metiamide or cimetidine. The vascular receptors stimulated by endogenous histamine may be distinctive from those stimulated by exogenous histamine, or the action of guanethidine may involve greater production of histamine at an intracellular site that is more readily reached by burimamide than by the other H2-antagonists.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Pharmacol. 1975 Apr;53(4):525-9 - PubMed
    1. Clin Exp Pharmacol Physiol. 1977 May-Jun;4(3):303-13 - PubMed
    1. Cardiovasc Res. 1975 Sep;9(5):697-706 - PubMed
    1. J Physiol. 1952 Dec;118(4):461-78 - PubMed
    1. Br J Pharmacol Chemother. 1953 Dec;8(4):412-9 - PubMed

MeSH terms

LinkOut - more resources